“…Acute pain through ASIC1 activation (Bohlen et al, 2011) Inflammatory pain, thermal hypersalgesia and mechanical allodynia (Zhang et al, 2017) Excitation of sensory neurons (Bohlen et al, 2011;Zhang et al, 2017) Neurogenic inflammation (Camara et al, 2003;Camargo et al, 2008) Non-neurogenic inflammation Endematogenic and pro-inflammatory (Camara et al, 2003;Casais-E-Silva et al, 2016;Costa et al, 2017) Inhibits platelet aggregation (Teixeira et al, 2011) Phospholipase activity (Gutierrez and Ownby, 2003) Myotoxic (Harris and Maltin, 1982) Pre-synaptic toxin, block of neuromuscular transmission leading to muscle paralysis (Sribar et al, 2014;Gutierrez et al, 2017) SVMP Inflammatory hyperalgesia (Fernandes et al, 2007;Bernardes et al, 2015;De Toni et al, 2015;Ferraz et al, 2015) Endematogenic activity independent of pro-inflammatory mediators (Laing et al, 2003) Cleavage of basement membrane of capillary vessels and endothelial cells adhesion proteins (Gutierrez et al, 2005;Escalante et al, 2011) Procoagulant through activation of prothrombin and Factor X (Takeda et al, 2012;Ainsworth et al, 2018) Inhibition of platelet aggregation (Kamiguti, 2005) Dermonecrotic activity dependent on TNF signaling (Laing et al, 2003) Potential paralysis through inhibition of α-7 neuronal AChR by the cysteine-rich and disintregin-like domains complex (Brust et al, 2013) SVSP Mild mechanical hyperalgesia (Menaldo et al, 2013) Leucocyte migration (Menaldo et al, 2013) Mild edema (Zychar et al, 2010) Procoagulant through activation of prothrombin and factors VII and X (Kini, 2005) Anti-coagulant through activation of Prot...…”